TG4050

TG4050 is an individualized therapeutic cancer vaccine developed for the treatment of solid tumors, particularly head and neck cancer. It is based on Transgene’s myvac platform and utilizes a modified Vaccinia virus Ankara (MVA) viral vector to deliver patient-specific neoantigens—mutations unique to each patient's tumor—selected using NEC’s Neoantigen Prediction System powered by artificial intelligence. Once injected, the vaccine stimulates the patient’s immune system to generate a targeted T-cell response against tumor cells expressing these neoantigens. Clinical trials have shown that TG4050 induces robust and sustained immune responses with promising early efficacy signals in preventing relapse after standard therapy in head and neck cancer patients. The vaccine is manufactured individually for each patient following sequencing of their tumor tissue[1][2][3][4][5][6][7].

Brand names

myvac

Other names

individualized MVA-based vaccine TG4050